Anebulo Pharmaceuticals, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD from Q2 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Anebulo Pharmaceuticals, Inc. quarterly/annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect history and growth rate from Q2 2020 to Q3 2024.
  • Anebulo Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending September 30, 2024 was -$1.69M, a 38% increase year-over-year.
  • Anebulo Pharmaceuticals, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was -$8.15M, a 147% decline from 2023.
  • Anebulo Pharmaceuticals, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was -$3.3M, a 39.3% increase from 2022.
  • Anebulo Pharmaceuticals, Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was -$5.44M, a 132% decline from 2021.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$1.69M +$1.04M +38% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q3 2023 -$2.73M -$7.39M -158% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q3 2022 $4.67M +$5.44M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q3 2021 -$778K -$643K -476% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q3 2020 -$135K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $3.02M Apr 23, 2020 Jun 30, 2020 10-K 2021-09-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.